BiomX announced positive results from their Phase 1b/2a trial evaluating BX004, a P. aeruginosa phage cocktail, in cystic fibrosis patients. They saw clinical improvement in pulmonary function and reduced bacterial burden, paving the way for a Phase 2b/3 trial.